(ZEG) AstraZeneca - Ratings and Ratios
Oncology, Respiratory, Cardiovascular, Immunology, Rare-Disease
ZEG EPS (Earnings per Share)
ZEG Revenue
Description: ZEG AstraZeneca
AstraZeneca PLC (XETRA:ZEG) is a global biopharmaceutical firm that discovers, develops, manufactures, and commercializes prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare-disease therapeutic areas.
The companys product portfolio includes flagship oncology agents such as Tagrisso, Imfinzi, Lynparza and Enhertu; cardiovascular and metabolic drugs like Farxiga, Brilinta and Crestor; respiratory treatments including Symbicort, Fasenra and Breztri; as well as vaccines and specialty biologics such as Evusheld and Soliris.
AstraZeneca serves primary-care and specialty physicians through a network of distributors and local sales offices in the United Kingdom, United States, Europe and Asia, leveraging both direct and partner-enabled channels to reach diverse markets.
Strategic partnerships augment its R&D pipeline: a multimodal oncology foundation model with Tempus, a quantum-accelerated chemistry platform with IonQ, a discovery collaboration with CSPC Pharmaceutical Group for oral candidates, and a lung-cancer program with Revna Biosciences.
Recent financial metrics (FY 2023) show total revenue of approximately £26 billion, with oncology sales growing ~15% YoY and R&D expenditure at £5.5 billion (≈21% of revenue), underscoring the companys focus on high-margin, innovative therapeutics.
Key sector drivers include an aging global population increasing demand for chronic-disease medicines, sustained venture-capital inflows into biotech accelerating early-stage innovation, and regulatory trends favoring accelerated approvals for breakthrough oncology and rare-disease treatments.
For a deeper, data-driven assessment of AstraZeneca’s valuation and risk profile, you may find it useful to explore the company’s analyst models on ValueRay.
ZEG Stock Overview
| Market Cap in USD | 268,906m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
ZEG Stock Ratings
| Growth Rating | 32.4% |
| Fundamental | 81.7% |
| Dividend Rating | 42.5% |
| Return 12m vs S&P 500 | -10.7% |
| Analyst Rating | - |
ZEG Dividends
| Dividend Yield 12m | 2.22% |
| Yield on Cost 5y | 4.01% |
| Annual Growth 5y | 1.98% |
| Payout Consistency | 96.7% |
| Payout Ratio | 57.5% |
ZEG Growth Ratios
| Growth Correlation 3m | 63.5% |
| Growth Correlation 12m | 15% |
| Growth Correlation 5y | 84% |
| CAGR 5y | 8.04% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.28 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.80 |
| Sharpe Ratio 12m | 0.87 |
| Alpha | -3.57 |
| Beta | 0.165 |
| Volatility | 21.64% |
| Current Volume | 12k |
| Average Volume 20d | 13.2k |
| Stop Loss | 140.3 (-3%) |
| Signal | 0.16 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (8.29b TTM) > 0 and > 6% of Revenue (6% = 3.39b TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 0.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.14% (prev -6.46%; Δ -1.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 13.39b > Net Income 8.29b (YES >=105%, WARN >=100%) |
| Net Debt (25.78b) to EBITDA (18.29b) ratio: 1.41 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.56b) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 81.38% (prev 82.08%; Δ -0.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.13% (prev 47.09%; Δ 5.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.76 (EBITDA TTM 18.29b / Interest Expense TTM 1.67b) >= 6 (WARN >= 3) |
Altman Z'' 0.86
| (A) -0.04 = (Total Current Assets 28.94b - Total Current Liabilities 33.54b) / Total Assets 112.42b |
| (B) 0.06 = Retained Earnings (Balance) 7.02b / Total Assets 112.42b |
| (C) 0.12 = EBIT TTM 12.98b / Avg Total Assets 108.38b |
| (D) 0.11 = Book Value of Equity 7.41b / Total Liabilities 67.61b |
| Total Rating: 0.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 81.71
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 2.78% = 1.39 |
| 3. FCF Margin 14.48% = 3.62 |
| 4. Debt/Equity 0.73 = 2.24 |
| 5. Debt/Ebitda 1.41 = 1.12 |
| 6. ROIC - WACC (= 8.15)% = 10.19 |
| 7. RoE 19.84% = 1.65 |
| 8. Rev. Trend 94.91% = 7.12 |
| 9. EPS Trend 47.54% = 2.38 |
What is the price of ZEG shares?
Over the past week, the price has changed by -2.69%, over one month by +10.58%, over three months by +20.98% and over the past year by +2.56%.
Is AstraZeneca a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZEG is around 125.29 EUR . This means that ZEG is currently overvalued and has a potential downside of -13.41%.
Is ZEG a buy, sell or hold?
What are the forecasts/targets for the ZEG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 136.6 | -5.6% |
ZEG Fundamental Data Overview
Market Cap USD = 268.91b (230.52b EUR * 1.1665 EUR.USD)
P/E Trailing = 32.6097
P/E Forward = 16.5563
P/S = 4.08
P/B = 5.8877
P/EG = 0.9804
Beta = 0.165
Revenue TTM = 56.50b USD
EBIT TTM = 12.98b USD
EBITDA TTM = 18.29b USD
Long Term Debt = 24.71b USD (from longTermDebt, last quarter)
Short Term Debt = 6.85b USD (from shortTermDebt, last quarter)
Debt = 32.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.78b USD (from netDebt column, last quarter)
Enterprise Value = 294.64b USD (268.91b + Debt 32.84b - CCE 7.11b)
Interest Coverage Ratio = 7.76 (Ebit TTM 12.98b / Interest Expense TTM 1.67b)
FCF Yield = 2.78% (FCF TTM 8.18b / Enterprise Value 294.64b)
FCF Margin = 14.48% (FCF TTM 8.18b / Revenue TTM 56.50b)
Net Margin = 14.68% (Net Income TTM 8.29b / Revenue TTM 56.50b)
Gross Margin = 81.38% ((Revenue TTM 56.50b - Cost of Revenue TTM 10.52b) / Revenue TTM)
Gross Margin QoQ = 82.89% (prev 83.51%)
Tobins Q-Ratio = 2.62 (Enterprise Value 294.64b / Total Assets 112.42b)
Interest Expense / Debt = 1.34% (Interest Expense 439.0m / Debt 32.84b)
Taxrate = 21.71% (679.0m / 3.13b)
NOPAT = 10.17b (EBIT 12.98b * (1 - 21.71%))
Current Ratio = 0.86 (Total Current Assets 28.94b / Total Current Liabilities 33.54b)
Debt / Equity = 0.73 (Debt 32.84b / totalStockholderEquity, last quarter 44.72b)
Debt / EBITDA = 1.41 (Net Debt 25.78b / EBITDA 18.29b)
Debt / FCF = 3.15 (Net Debt 25.78b / FCF TTM 8.18b)
Total Stockholder Equity = 41.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.38% (Net Income 8.29b / Total Assets 112.42b)
RoE = 19.84% (Net Income TTM 8.29b / Total Stockholder Equity 41.82b)
RoCE = 19.52% (EBIT 12.98b / Capital Employed (Equity 41.82b + L.T.Debt 24.71b))
RoIC = 14.17% (NOPAT 10.17b / Invested Capital 71.75b)
WACC = 6.01% (E(268.91b)/V(301.74b) * Re(6.62%) + D(32.84b)/V(301.74b) * Rd(1.34%) * (1-Tc(0.22)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.06%
[DCF Debug] Terminal Value 80.01% ; FCFE base≈7.70b ; Y1≈8.73b ; Y5≈11.91b
Fair Price DCF = 133.0 (DCF Value 206.17b / Shares Outstanding 1.55b; 5y FCF grow 15.61% → 3.0% )
EPS Correlation: 47.54 | EPS CAGR: 10.80% | SUE: N/A | # QB: 0
Revenue Correlation: 94.91 | Revenue CAGR: 10.51% | SUE: N/A | # QB: 0